Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Produits et services

pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions, namely, acute bronchitis, allergies, arthritis, asthma, cancer, cellulitis, cirrhosis, common cold, cold sore, conjunctivitis, cystitis, diabetes, diarrhea, ear infection, fever, fibromyalgia, fungal infection, gastroenteritis, headaches, hemorrhoids, high cholesterol, hyperglycemia, hypoglycemia, indigestion, irritable bowel syndrome, influenza, laryngitis, lyme disease, meningitis, mononucleosis, osteoporosis, pneumonia, pyelonephritis, rosacea, sinusitis, skin abscess, stomach aches, and streptococcal pharyngitis Medical devices for the purposes of lowering cholesterol Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management Licensing of intellectual property

Produits et services

pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions, namely, acute bronchitis, allergies, arthritis, asthma, cancer, cellulitis, cirrhosis, common cold, cold sore, conjunctivitis, cystitis, diabetes, diarrhea, ear infection, fever, fibromyalgia, fungal infection, gastroenteritis, headaches, hemorrhoids, high cholesterol, hyperglycemia, hypoglycemia, indigestion, irritable bowel syndrome, influenza, laryngitis, lyme disease, meningitis, mononucleosis, osteoporosis, pneumonia, pyelonephritis, rosacea, sinusitis, skin abscess, stomach aches, and streptococcal pharyngitis Medical devices for the purposes of lowering cholesterol Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management Licensing of intellectual property

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Produits et services

Pharmaceutical preparations.

Produits et services

(1) Pharmaceutical preparations

Produits et services

Pharmaceutical preparations for the treatment of rare metabolic and neurological disorders and lysosomal storage diseases; Pharmaceutical preparations for the treatment of cholesterol metabolism disorders and lysosomal storage diseases

Produits et services

Pharmaceutical preparations for the treatment of rare metabolic and neurological disorders and lysosomal storage diseases; Pharmaceutical preparations for the treatment of cholesterol metabolism disorders and lysosomal storage diseases

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Produits et services

Pharmaceutical preparations for the treatment of rare neurological disorders, not including dermatological disorders

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Produits et services

Pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions. Medical devices for the purposes of lowering cholesterol. Business brokerage services and related consulting pertaining to business sales. Business brokerage services and related consulting pertaining to mergers, acquisitions and business valuations (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); intellectual property venture fund management services; holding company services performed for third parties, namely, investment management. Research and development of new products, pharmaceutical preparations, and medical devices; scientific, medical, and pharmaceutical research and development; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; conducting research and clinical trials in the field of medicine, medical devices, and pharmaceuticals. Licensing of intellectual property.

Produits et services

Pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions. Medical devices for the purposes of lowering cholesterol. Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; intellectual property venture fund management services; holding company services performed for third parties, namely, investment management. Research and development of new products, pharmaceutical preparations, and medical devices; scientific, medical, and pharmaceutical research and development; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; conducting research and clinical trials in the field of medicine, medical devices, and pharmaceuticals. Licensing of intellectual property.

Produits et services

Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations. Intellectual property venture fund management services; Financial holding company services performed for third parties, namely, investment management. Licensing of intellectual property.

Produits et services

Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations. Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management. Licensing of intellectual property.

Produits et services

(1) Pharmaceutical and biological preparations for medical use, namely, for the prevention and treatment of lysosomal disorders and elevated cholesterol levels (2) Medical devices for the purposes of lowering cholesterol (1) Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management (2) Research and development of new products, pharmaceutical preparations, and medical devices; providing scientific research information in the fields of pharmaceuticals, medical diagnosis, and treatments; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; Conducting research and clinical trials in the field of medicine, medical devices, and pharmaceuticals (3) Licensing of intellectual property

Produits et services

(1) Pharmaceutical and biological preparations for medical use, namely, for the prevention and treatment of lysosomal disorders and elevated cholesterol levels (2) Medical devices for the purposes of lowering cholesterol. (1) Business acquisition and merger consultation. (2) Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management (3) Research and development of new products, pharmaceutical preparations, and medical devices; providing scientific research information in the fields of pharmaceuticals, medical diagnosis, and treatments; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; Conducting research and clinical trials in the field of medicine, medical devices, and pharmaceuticals (4) Licensing of intellectual property.

Produits et services

Research and development of new products, pharmaceutical preparations, and medical devices; scientific, medical, and pharmaceutical research and development; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; Conducting research and clinical trials for others in the field of medicine, medical devices, and pharmaceuticals

Produits et services

pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions, namely, acute bronchitis, allergies, arthritis, asthma, cancer, cellulitis, cirrhosis, common cold, cold sore, conjunctivitis, cystitis, diabetes, diarrhea, ear infection, fever, fibromyalgia, fungal infection, gastroenteritis, headaches, hemorrhoids, high cholesterol, hyperglycemia, hypoglycemia, indigestion, irritable bowel syndrome, influenza, laryngitis, lyme disease, meningitis, mononucleosis, osteoporosis, pneumonia, pyelonephritis, rosacea, sinusitis, skin abscess, stomach aches, and streptococcal pharyngitis Medical devices for the purposes of lowering cholesterol Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management Licensing of intellectual property

Produits et services

pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions, namely, acute bronchitis, allergies, arthritis, asthma, cancer, cellulitis, cirrhosis, common cold, cold sore, conjunctivitis, cystitis, diabetes, diarrhea, ear infection, fever, fibromyalgia, fungal infection, gastroenteritis, headaches, hemorrhoids, high cholesterol, hyperglycemia, hypoglycemia, indigestion, irritable bowel syndrome, influenza, laryngitis, lyme disease, meningitis, mononucleosis, osteoporosis, pneumonia, pyelonephritis, rosacea, sinusitis, skin abscess, stomach aches, and streptococcal pharyngitis Medical devices for the purposes of lowering cholesterol Business brokerage services and related consulting pertaining to business sales, mergers, acquisitions and business valuations; Intellectual property venture fund management services; Holding company services performed for third parties, namely, investment management Licensing of intellectual property

Produits et services

Research and development of new products, pharmaceutical preparations, and medical devices; scientific, medical, and pharmaceutical research and development; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; Conducting research and clinical trials for others in the field of medicine, medical devices, and pharmaceuticals

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61K 31/724 - Cyclodextrines

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Classes IPC  ?

• A61K 31/724 - Cyclodextrines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions